Man Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Man Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Hold	0	–	-$3.5M	–	2032
2023 Q3	–	Hold	0	–	–	–	995

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Man Group's XBI Position: Q2 2026 in Review

Man Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 992% in Q2 2026, buying an estimated $4.39M and bringing the position to 35,717 shares worth $5.65M. The position accounts for 0.01% of the portfolio, ranked #1073.

Man Group first reported a position in XBI in Q2 2018 and has held it in 7 quarters since. The position peaked at $8.99M in Q4 2023. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Man Group held 35,717 shares of State Street SPDR S&P Biotech ETF worth $5.65M as of Q2 2026.
Man Group bought 32,447 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $4.39M.
State Street SPDR S&P Biotech ETF made up 0.01% of Man Group's portfolio in Q2 2026, its #1073 holding.
Man Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 7 quarters since.
Man Group's State Street SPDR S&P Biotech ETF position peaked at $8.99M in Q4 2023.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.